

Gender: Male | Birth year: 1950 | WHO: 0

Tumor: Lung - Adenocarcinoma | Lesions: Liver | Stage: IV

Summary

Clinical summary

Relevant systemic treatment history	1/2023-9/2024	Osimertinib
Relevant other oncological history	None	
Previous primary tumor	None	
Relevant non-oncological history	2022	Rheumatoid arthritis

Recent molecular results

Hartwig WGS (20-Aug.-2024)

Biopsy location	Liver (purity 50%)
Molecular tissue of origin prediction	Lung: Non-small cell (98%)
Tumor mutational load / burden	TML low (40) / TMB low (2)
Microsatellite (in)stability	Stable
HR status	Proficient (0)
High driver mutations	EGFR L858R, EGFR C797S, KRAS G12D
Amplified genes	None
Deleted genes	TP53
Homozygously disrupted genes	None
Gene fusions	None
Virus detection	None
Potentially actionable events with medium/low driver:	None

IHC resultsPD-L1: Score 1%

Example trials that are open and potentially eligible (2 cohorts from 2 trials)

Trial	Cohort	Molecular	Warnings
METC 04 TEDR1	Lung cancer C797S cohort	EGFR C797S	None
METC 02 KAYRAS	Dose expansion - monotherapy - NSCLC	KRAS G12D	Variant(s) KRAS G12D in KRAS but subclonal likelihood of > 50%

Example trials that are open and potentially eligible but currently have no slots available (1 cohort from 1 trial)

Trial	Cohort	Molecular	Warnings
METC 01 IEMOEN	Dose escalation - monotherapy		Hemoglobin 5.6 mmol/L below min of 6.0 mmol/L, History of rheumatoid arthritis, SOC not exhausted: at least platinum doublet remaining

Trial Matching Summary

Example trials and cohorts that meet molecular requirements and may be eligible, but are closed (0)

None

Example trials and cohorts that are open but considered ineligible (2)

Trial	Cohort	Molecular	Ineligibility reasons
METC 02 KAYRAS	Dose expansion - monotherapy - Colorectum	KRAS G12D	Tumor type
METC 03 NO-SEE797ES	Dose escalation - monotherapy		C797S detected in EGFR

Open cohorts with no slots available are shown in grey.